Aliases & Classifications for Keratosis

MalaCards integrated aliases for Keratosis:

Name: Keratosis 12 44 15 17 71
Actinic Keratosis 71
Hyperkeratosis 71

Classifications:



External Ids:

Disease Ontology 12 DOID:161
MeSH 44 D007642
NCIt 50 C34747
SNOMED-CT 67 254666005
UMLS 71 C0022593 C0022602 C0870082

Summaries for Keratosis

Disease Ontology : 12 A skin disease characterized by growth of keratin on the skin or mucous membranes.

MalaCards based summary : Keratosis, also known as actinic keratosis, is related to keratosis follicularis spinulosa decalvans and keratosis, seborrheic, and has symptoms including pruritus, exanthema and trichorrhexis invaginata. An important gene associated with Keratosis is CTSC (Cathepsin C), and among its related pathways/superpathways are Developmental Biology and Keratinization. The drugs Diclofenac and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include skin, tongue and kidney, and related phenotypes are growth/size/body region and immune system

Wikipedia : 74 Keratosis (from kerat- + -osis) is a growth of keratin on the skin or on mucous membranes stemming from... more...

Related Diseases for Keratosis

Diseases related to Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 461)
# Related Disease Score Top Affiliating Genes
1 keratosis follicularis spinulosa decalvans 33.0 SAT1 MBTPS2 LRP1
2 keratosis, seborrheic 32.9 PIK3CA KRT5 KRT10 FGFR3
3 darier-white disease 32.9 SAT1 MBTPS2 DSP ATP2A2
4 punctate palmoplantar keratoderma 32.2 SERPINB7 GJB2
5 erythrokeratodermia variabilis et progressiva 1 32.0 LORICRIN KRT10 KRT1 GJB2 GJA1
6 striate palmoplantar keratoderma 32.0 SERPINB7 KRT10 KRT1 DSP CTSC
7 palmoplantar keratoderma, epidermolytic 32.0 SERPINB7 KRT9 KRT16 KRT10 KRT1 DSP
8 clear cell acanthoma 32.0 KRT10 FLG
9 ichthyosis vulgaris 31.9 LORICRIN KRT10 KRT1 FLG
10 hereditary palmoplantar keratoderma 31.8 KRT9 GJB2
11 ichthyosis follicularis atrichia photophobia syndrome 31.8 MBTPS2 GJB2
12 focal palmoplantar keratoderma 31.6 KRT16 GJB2
13 acrokeratoderma, hereditary papulotranslucent 31.6 KRT9 KRT1 GJB2
14 mutilating palmoplantar keratoderma with periorificial keratotic plaques 31.5 SERPINB7 MBTPS2 LORICRIN KRT10
15 diffuse palmoplantar keratoderma 31.5 KRT9 KRT5 KRT1 DSP
16 palmoplantar keratoderma, nonepidermolytic 31.5 KRT9 KRT16 KRT1 GJA1 DSP
17 vohwinkel syndrome 31.5 LORICRIN GJB2 GJA1
18 bowen's disease 31.2 KRT16 KRT10
19 alopecia 31.2 MBTPS2 GJA1 FLG DSP
20 palmoplantar keratosis 31.1 SERPINB7 LORICRIN KRT9 KRT5 KRT16 KRT10
21 lichen planus 31.0 KRT16 KRT10 KRT1 FLG
22 dermatosis papulosa nigra 31.0 PIK3CA FGFR3
23 skin carcinoma 30.9 PIK3CA LORICRIN KRT5 KRT10 KRT1 FLG
24 papilloma 30.7 KRT5 KRT10 KRT1 FLG FGFR3
25 keratoacanthoma 30.7 KRT16 KRT10 FLG
26 cholesteatoma of middle ear 30.6 KRT16 KRT10 FLG
27 skin atrophy 30.5 LORICRIN GJA1 FLG
28 acanthoma 30.5 PIK3CA KRT5 KRT10 KRT1 FGFR3
29 eccrine acrospiroma 30.5 KRT5 KRT10
30 skin benign neoplasm 30.4 KRT5 KRT1 FGFR3
31 discoid lupus erythematosus 30.3 KRT16 KRT10 FLG
32 hypotrichosis 30.3 KRT5 GJB2 GJA1 FLG CTSC
33 eccrine porocarcinoma 30.3 KRT5 KRT1
34 nevus, epidermal 30.2 PIK3CA KRT10 KRT1 GJB2 FGFR3
35 ainhum 30.1 LORICRIN GJB2
36 large cell acanthoma 30.1 KRT5 KRT10
37 keratitis-ichthyosis-deafness syndrome, autosomal dominant 30.1 GJB2 GJA1
38 porokeratosis 30.0 LORICRIN KRT16 KRT1 GJB2 FLG FGFR3
39 psoriasis 30.0 LORICRIN KRT5 KRT16 KRT10 KRT1 FLG
40 bart-pumphrey syndrome 30.0 GJB2 GJA1
41 ichthyosis, cyclic, with epidermolytic hyperkeratosis 30.0 KRT10 KRT1
42 acantholytic acanthoma 29.9 KRT5 ATP2A2
43 ichthyosis, x-linked 29.9 MBTPS2 KRT10 KRT1 FLG
44 knuckle pads 29.9 KRT9 GJB2 GJA1
45 ectodermal dysplasia 29.9 KRT16 GJB2 GJA1 FGFR3 DSP
46 keratoderma, palmoplantar, with deafness 29.8 GJB2 GJA1
47 pinguecula 29.8 KRT16 KRT10
48 pseudoainhum 29.8 LORICRIN GJB2 GJA1
49 ichthyosis 29.6 POMP MBTPS2 LORICRIN KRT5 KRT16 KRT10
50 epidermolytic hyperkeratosis 29.6 LORICRIN KRT9 KRT5 KRT16 KRT10 KRT1

Comorbidity relations with Keratosis via Phenotypic Disease Network (PDN):


Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Keratosis, Seborrheic

Graphical network of the top 20 diseases related to Keratosis:



Diseases related to Keratosis

Symptoms & Phenotypes for Keratosis

UMLS symptoms related to Keratosis:


pruritus, exanthema, trichorrhexis invaginata

MGI Mouse Phenotypes related to Keratosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.97 ATP2A2 CTSC DSP FGFR3 GJA1 GJB2
2 immune system MP:0005387 9.7 ATP2A2 CTSC DSP FGFR3 GJA1 GJB2
3 integument MP:0010771 9.32 ATP2A2 CTSC DSP FGFR3 GJA1 GJB2

Drugs & Therapeutics for Keratosis

Drugs for Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Prilocaine Approved Phase 4 721-50-6 4906
4
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
5
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
6
Menthol Approved Phase 4 2216-51-5 16666
7
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
8
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
9
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
10
Aminolevulinic acid Approved Phase 4 106-60-5 137
11
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
13 Radiation-Protective Agents Phase 4
14 Anti-Infective Agents Phase 4
15 Anti-Inflammatory Agents Phase 4
16 Analgesics, Non-Narcotic Phase 4
17 Retinol palmitate Phase 4
18 Cyclooxygenase Inhibitors Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4
20 retinol Phase 4
21 Analgesics Phase 4
22 Antirheumatic Agents Phase 4
23 Protective Agents Phase 4
24 Sodium Channel Blockers Phase 4
25 Diuretics, Potassium Sparing Phase 4
26 Anesthetics, Local Phase 4
27 Anti-Infective Agents, Local Phase 4
28 Anti-Bacterial Agents Phase 4
29 Viscosupplements Phase 4
30 Pharmaceutical Solutions Phase 4
31 Immunologic Factors Phase 4
32 Adjuvants, Immunologic Phase 4
33 interferons Phase 4
34 Methyl 5-aminolevulinate Phase 4
35 Emollients Phase 4
36
Tavaborole Approved, Investigational Phase 3 174671-46-6
37
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
38
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
39
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
40
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
41
Selenious acid Approved, Investigational Phase 3 7783-00-8
42 Antifungal Agents Phase 3
43 Keratolytic Agents Phase 3
44
Ethylene Phase 3 74-85-1 6325
45 Salicylates Phase 3
46 Antioxidants Phase 3
47 Sodium Selenite Phase 3
48 Sunscreening Agents Phase 3
49 Anesthetics Phase 3
50 Liver Extracts Phase 3

Interventional clinical trials:

(show top 50) (show all 318)
# Name Status NCT ID Phase Drugs
1 A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
2 Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study Unknown status NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
3 A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis. Unknown status NCT01656226 Phase 4
4 Comparative Intraindividual Study, About the Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between Acid Methyl Aminolevulinate Cream and Aminolevulinic Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
5 An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
6 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA) Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
7 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
8 Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
9 Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
10 A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Density of Ablative Laser Channel in the Treatment of Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
11 Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
12 A Randomized Right/Left Clinical Trial to Evaluate the Use of Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine;Polysporin
13 A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT) Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
14 Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
15 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
16 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT Completed NCT01000636 Phase 4
17 A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
18 Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Completed NCT03697590 Phase 4 No curettage;Curettage
19 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Completed NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
20 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
21 A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial Completed NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
22 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
23 A Randomized Study to Evaluate the Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization Compared to Cryotherapy Completed NCT02990221 Phase 4 Ingenol mebutate
24 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Completed NCT02984072 Phase 4 Menthol;Aqueous Cream
25 Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
26 UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
27 An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage Completed NCT03487588 Phase 4 A-101 Topical Solution
28 A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
29 Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
30 A Randomized, Evaluator-blinded, Bilateral Comparison of the Treatment of Facial Actinic Keratoses Using Combination Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Different Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
31 A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
32 Prospective, Randomized, Controlled, Multicenter, Two-armed, Study Comparing Daylight Photodynamic Therapy Using MAL With Cryosurgery for the Treatment and Prophylaxis of Actinic Keratoses in Photodamaged Skin of the Face Completed NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
33 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
34 An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands Completed NCT02251652 Phase 4 Ingenol Mebutate
35 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
36 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter-clinical Trial Recruiting NCT03642535 Phase 4 ALA
37 A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses Recruiting NCT03963102 Phase 4 Ameluz
38 An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
39 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
40 Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
41 A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES Unknown status NCT00002811 Phase 3 liposomal T4N5 lotion
42 Phase III Comparative Study About the Use of 5% 5-fluorouracil Cream Versus Its Utilization as Agent for Sequential Superficial Peeling in the Treatment of Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
43 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
44 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
45 A Phase 3b Randomized, Double-blinded, Placebo-controlled, Multicenter, Efficacy and Safety Study of Imiquimod Cream Following Cryosurgery for the Treatment of Actinic Keratoses Completed NCT00894647 Phase 3 imiquimod cream;placebo cream
46 Safety and Efficacy of Photodynamic Therapy With Short Incubation Methylaminolevulinate Without Occlusion in the Treatment of Actinic Keratoses. Completed NCT00926952 Phase 3 Methylaminolevulinate (Metvix, Metvixia)
47 Phase 3 Study of Brand Generic and Placebo in Treatment of Actinic Keratosis Completed NCT01354717 Phase 3 Brand Carac;Generic 0.5% 5-fluorouracil cream
48 Evaluation of the Formulation of 5-aminolevulinic Acid With Dimethylsulfoxide in Photodynamic Therapy for Treatment of Actinic Keratosis Completed NCT01459393 Phase 3 5-ALA Photodynamic Therapy;Cryotherapy with liquid nitrogen
49 A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT Completed NCT02799082 Phase 3 Vehicle;BF-200 ALA
50 A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of a Nanoemulsion Gel Formulation BF-200 ALA, in Comparison With Metvix® and Placebo, for the Treatment of Actinic Keratosis With PDT Completed NCT02799069 Phase 3 BF-200 ALA;MAL Cream;Vehicle

Search NIH Clinical Center for Keratosis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Fluorouracil
Masoprocol

Cochrane evidence based reviews: keratosis

Genetic Tests for Keratosis

Anatomical Context for Keratosis

MalaCards organs/tissues related to Keratosis:

40
Skin, Tongue, Kidney, Breast, Eye, Myeloid, T Cells

Publications for Keratosis

Articles related to Keratosis:

(show top 50) (show all 10394)
# Title Authors PMID Year
1
X-linked ichthyosis: an oculocutaneous genodermatosis. 61 54
20080321 2010
2
Pathogenesis, clinical features and pathology of chronic arsenicosis. 61 54
19171978 2008
3
Functional Cathepsin C mutations cause different Papillon-Lefèvre syndrome phenotypes. 54 61
18294227 2008
4
Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study. 61 54
16911278 2006
5
A novel threonine to proline mutation in the helix termination motif of keratin 1 in epidermolytic hyperkeratosis with severe palmoplantar hyperkeratosis and contractures of the digits. 54 61
15888189 2005
6
Sensorineural hearing loss, striate palmoplantar hyperkeratosis, and knuckle pads in a patient with a novel connexin 26 (GJB2) mutation. 54 61
15635064 2005
7
Expression of keratins 14, 10 and 16 in marginal keratoderma of the palms. 54 61
16356392 2005
8
Atypical epidermolytic palmoplantar keratoderma presentation associated with a mutation in the keratin 1 gene. 61 54
15214894 2004
9
Novel keratin 14 gene mutations in patients from Hungary with epidermolysis bullosa simplex. 54 61
14987259 2004
10
Epidermal hyperproliferation and decreased skin barrier function in mice overexpressing stratum corneum chymotryptic enzyme. 54 61
15040472 2004
11
De novo mutations in monilethrix. 61 54
14714571 2003
12
Disruption of the suprabasal keratin network by mutation M150T in the helix initiation motif of keratin 10 does not affect cornified cell envelope formation in human epidermis. 61 54
14705805 2003
13
Genetic heterogeneity in erythrokeratodermia variabilis: novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlations. 54 61
12648223 2003
14
Loricrin keratoderma: a novel disease entity characterized by nuclear accumulation of mutant loricrin. 54 61
12615358 2003
15
Transgenic mice over-expressing a serine protease in the skin: evidence of interferon gamma-independent MHC II expression by epidermal keratinocytes. 61 54
14609096 2003
16
Expression of gap junction proteins (connexin 26, 30, 32, 43) in normal mucosa, hyperkeratosis and carcinoma of the human larynx. 54 61
12417773 2002
17
Epidermal expression of serine protease, neuropsin (KLK8) in normal and pathological skin samples. 54 61
12147714 2002
18
Upregulation of human beta-defensin 2 peptide expression in oral lichen planus, leukoplakia and candidiasis. an immunohistochemical study. 54 61
12389997 2002
19
Expression of a truncated keratin 5 may contribute to severe palmar--plantar hyperkeratosis in epidermolysis bullosa simplex patients. 54 61
11407989 2001
20
Epithelial-mesenchymal interactions in wounds: treatment of palmoplantar wounds by nonpalmoplantar pure epidermal sheet grafts. 54 61
11346340 2001
21
Evidence for novel functions of the keratin tail emerging from a mutation causing ichthyosis hystrix. 61 54
11286616 2001
22
[Hope for new therapies of severe genetic skin diseases]. 54 61
11079322 2000
23
Transgenic coexpression of v-Ha-ras and transforming growth factor alpha increases epidermal hyperproliferation and tumorigenesis and predisposes to malignant conversion via endogenous c-Ha-ras activation. 54 61
10708482 2000
24
A connexin 26 mutation causes a syndrome of sensorineural hearing loss and palmoplantar hyperkeratosis (MIM 148350). 54 61
10633135 2000
25
Clustered cadherin genes: a sequence-ready contig for the desmosomal cadherin locus on human chromosome 18. 54 61
10644442 1999
26
Mutations of the cathepsin C gene are responsible for Papillon-Lefèvre syndrome. 54 61
10593994 1999
27
Epidermolytic hyperkeratosis with polycyclic psoriasiform plaques resulting from a mutation in the keratin 1 gene. 54 61
10597140 1999
28
Regulation of keratin 9 in nonpalmoplantar keratinocytes by palmoplantar fibroblasts through epithelial-mesenchymal interactions. 54 61
10201533 1999
29
Severe palmo-plantar hyperkeratosis in Dowling-Meara epidermolysis bullosa simplex caused by a mutation in the keratin 14 gene (KRT14). 54 61
9804355 1998
30
Translocation of profilaggrin N-terminal domain into keratinocyte nuclei with fragmented DNA in normal human skin and loricrin keratoderma. 54 61
9800950 1998
31
Topical application of viral vectors for epidermal gene transfer. 54 61
9129236 1997
32
Genetic approaches to understanding the keratinopathies. 54 61
8973737 1997
33
Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. 54 61
7969162 1994
34
Keratin 9 gene mutations in epidermolytic palmoplantar keratoderma (EPPK). 54 61
7512862 1994
35
Targeted overexpression of transforming growth factor alpha in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous, squamous papillomas. 54 61
8117621 1993
36
Skin hyperkeratosis and papilloma formation in transgenic mice expressing a ras oncogene from a suprabasal keratin promoter. 54 61
1696852 1990
37
Xeroderma pigmentosum in Yemen. 61
33538348 2021
38
Thymoquinone loaded calcium alginate and polyvinyl alcohol carrier inhibits the 7,12-dimethylbenz[a]anthracene-induced hamster oral cancer via the down-regulation of PI3K/AKT/mTOR signaling pathways. 61
33068063 2021
39
It has the Erythema of a Lichen Planopilaris, it has the Hyperkeratosis of a Lichen Planopilaris, but it is Not a Lichen Planopilaris: About the "Lichen Planopilaris-Like" Form of Folliculitis Decalvans. 61
32769552 2021
40
Clinical and macroscopic morphological features of canine tungiasis. 61
33474585 2021
41
Clinical and dermatoscopic characteristics of lichen planus-like keratosis in a West-Asian population. 61
33200822 2021
42
Dermatoscopic Findings and Dermatopathological Correlates in Clinical Variants of Actinic Keratosis, Bowen's Disease, Keratoacanthoma and Squamous Cell Carcinoma. 61
33583118 2021
43
Effect of Gentamicin Ointment in Patients with Nagashima-type Palmoplantar Keratosis: A Double-blind Vehicle-controlled Study. 61
33554268 2021
44
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. 61
33567191 2021
45
Comparative study of imiquimod 3,75% vs. photodynamic therapy for actinic keratosis of the scalp. 61
33566432 2021
46
Treatment of Actinic Keratosis: Does Effectiveness Depend on the Location? 61
33504437 2021
47
Photodynamic therapy for actinic keratosis in vegan and omnivore patients: the role of diet on skin healing. 61
31076007 2021
48
Chemoprevention of keratinocyte carcinoma and actinic keratosis in solid-organ transplant recipients: Systematic review and meta-analyses. 61
32387631 2021
49
Patient-reported outcomes of topical therapies in actinic keratosis: a systematic review. 61
33527673 2021
50
Interventions for Actinic Keratosis in Nonscalp and Nonface Localizations: Results from a Systematic Review with Network Meta-Analysis. 61
32645365 2021

Variations for Keratosis

Expression for Keratosis

Search GEO for disease gene expression data for Keratosis.

Pathways for Keratosis

GO Terms for Keratosis

Cellular components related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.13 SERPINB7 SAT1 POMP PIK3CA MBTPS2 LRP1
2 cornified envelope GO:0001533 9.35 LORICRIN KRT10 KRT1 FLG DSP
3 intercalated disc GO:0014704 9.33 PIK3CA GJA1 DSP
4 fascia adherens GO:0005916 9.32 GJA1 DSP
5 intermediate filament GO:0005882 9.17 KRT9 KRT5 KRT16 KRT10 KRT1 FLG

Biological processes related to Keratosis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.76 LRP1 KRT16 GJB2 CTSC
2 keratinization GO:0031424 9.7 LORICRIN KRT9 KRT5 KRT16 KRT10 KRT1
3 epidermis development GO:0008544 9.67 KRT9 KRT5 DSP ATP2A2
4 keratinocyte differentiation GO:0030216 9.65 LORICRIN KRT16 KRT10 FLG DSP
5 intermediate filament organization GO:0045109 9.55 KRT9 DSP
6 protein heterotetramerization GO:0051290 9.54 KRT10 KRT1
7 relaxation of cardiac muscle GO:0055119 9.52 PIK3CA ATP2A2
8 negative regulation of myelination GO:0031642 9.51 KLK8 CTSC
9 establishment of skin barrier GO:0061436 9.5 KRT16 KRT1 FLG
10 gap junction assembly GO:0016264 9.49 GJB2 GJA1
11 cell communication by electrical coupling GO:0010644 9.48 GJB2 GJA1
12 epididymis development GO:1905867 9.43 GJB2 GJA1
13 bone maturation GO:0070977 9.4 MBTPS2 FGFR3
14 peptide cross-linking GO:0018149 9.35 LORICRIN KRT10 KRT1 FLG DSP
15 cornification GO:0070268 9.23 LORICRIN KRT9 KRT5 KRT16 KRT10 KRT1

Molecular functions related to Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.55 KRT9 KRT16 KRT10 FLG DSP
2 structural constituent of cytoskeleton GO:0005200 9.35 LORICRIN KRT9 KRT5 KRT16 DSP
3 gap junction channel activity involved in cell communication by electrical coupling GO:1903763 9.26 GJB2 GJA1
4 structural constituent of epidermis GO:0030280 8.92 LORICRIN KRT10 KRT1 FLG

Sources for Keratosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....